ARS Pharmaceuticals Valuation
| SPRY Stock | 9.67 0.47 4.64% |
At this time, the firm appears to be overvalued. ARS Pharmaceuticals shows a prevailing Real Value of USD8.22 per share. The current price of the firm is USD9.67. Our model approximates the value of ARS Pharmaceuticals from analyzing the firm fundamentals such as profit margin of (0.56) %, and Return On Equity of -0.46 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting ARS Pharmaceuticals' valuation include:
Price Book 6.795 | Enterprise Value | Enterprise Value Ebitda (9.88) | Price Sales 6.6951 | Enterprise Value Revenue 5.6935 |
Overvalued
Today
Please note that ARS Pharmaceuticals' price fluctuation is slightly risky at this time. Calculation of the real value of ARS Pharmaceuticals is based on 3 months time horizon. Increasing ARS Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since ARS Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of ARS Stock. However, ARS Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 9.67 | Real 8.22 | Target 28.83 | Hype 9.67 | Naive 9.63 |
The intrinsic value of ARS Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence ARS Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of ARS Pharmaceuticals helps investors to forecast how ARS stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of ARS Pharmaceuticals more accurately as focusing exclusively on ARS Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use ARS Pharmaceuticals' intrinsic value based on its ongoing forecasts of ARS Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against ARS Pharmaceuticals' closest peers.
ARS Pharmaceuticals Cash |
|
ARS Pharmaceuticals Total Value Analysis
ARS Pharmaceuticals is at this time projected to have valuation of 812.87 M with market capitalization of 955.87 M, debt of 42 K, and cash on hands of . Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the ARS Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
812.87 M | 955.87 M | 42 K |
ARS Pharmaceuticals Investor Information
About 17.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.77. ARS Pharmaceuticals had not issued any dividends in recent years. Based on the key indicators related to ARS Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, ARS Pharmaceuticals may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.ARS Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. ARS Pharmaceuticals has an asset utilization ratio of 25.39 percent. This suggests that the Company is making USD0.25 for each dollar of assets. An increasing asset utilization means that ARS Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.ARS Pharmaceuticals Profitability Analysis
Based on ARS Pharmaceuticals' profitability indicators, ARS Pharmaceuticals' profitability may be sliding down. It has an above-average odds of reporting lower numbers next quarter. Profitability indicators assess ARS Pharmaceuticals' ability to earn profits and add value for shareholders.Net Income | First Reported 2019-12-31 | Previous Quarter -44.9 M | Current Value -51.2 M | Quarterly Volatility 18.4 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.52 | 0.69 |
|
|
For ARS Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of ARS Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well ARS Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between ARS Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of ARS Pharmaceuticals over time as well as its relative position and ranking within its peers.
ARS Pharmaceuticals Earnings per Share Projection vs Actual
By analyzing ARS Pharmaceuticals' earnings estimates, investors can diagnose different trends across ARS Pharmaceuticals' analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for ARS Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.ARS Pharmaceuticals Ownership Allocation
ARS Pharmaceuticals holds a total of 98.85 Million outstanding shares. The majority of ARS Pharmaceuticals outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in ARS Pharmaceuticals to benefit from reduced commissions. Therefore, institutional investors are subject to a different set of regulations than regular investors in ARS Pharmaceuticals. Please pay attention to any change in the institutional holdings of ARS Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Also note that nearly six million one hundred sixty-eight thousand one hundred fifty-three invesors are currently shorting ARS Pharmaceuticals expressing very little confidence in its future performance.ARS Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 89.15 M. Net Income was 8 M with profit before overhead, payroll, taxes, and interest of 114.87 M.About ARS Pharmaceuticals Valuation
Our relative valuation model uses a comparative analysis of ARS Pharmaceuticals. We calculate exposure to ARS Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of ARS Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 78.9 M | 82.8 M | |
| Pretax Profit Margin | 0.09 | 0.11 | |
| Operating Profit Margin | (0.04) | (0.04) | |
| Net Profit Margin | 0.10 | 0.11 | |
| Gross Profit Margin | 0.69 | 0.52 |
ARS Pharmaceuticals Current Valuation Indicators
Valuation refers to the process of determining the present value of ARS Pharmaceuticals and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value ARS we look at many different elements of the entity such as ARS's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as ARS Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use ARS Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes ARS Pharmaceuticals' worth.Additional Tools for ARS Stock Analysis
When running ARS Pharmaceuticals' price analysis, check to measure ARS Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ARS Pharmaceuticals is operating at the current time. Most of ARS Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ARS Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ARS Pharmaceuticals' price. Additionally, you may evaluate how the addition of ARS Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.